|
Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.
|
|
INDICATIONS
|
ALOCRIL® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis.
|
|
MECHANISM OF ACTION
|
Mast Cell Stabilizer (2nd generation)
|
|
MICROBIOLOGY
|
Nedocromil sodium inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and decreased activation of eosinophils have also been demonstrated. Als inhibits histamine release from a population of mast cells having been defined as belonging to the mucosal sub type and inhibits beta-glucuronidase release from macrophages.
|
|
CONTRAINDICATIONS & WARNINGS
|
ALOCRIL® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients.
|
|
PEDIATRIC USE
|
Safety and effectiveness in children below the age of 3 years have not been established.
|
|
PREGNANCY
|
Category B Teratogenic Effects Reproduction studies performed in mice, rats and rabbits using a subcutaneous dose of 100 mg/kg/day (more than 1600 times the maximum human daily ocular dose on a mg/kg basis) revealed no evidence of teratogenicity or harm to the fetus due to nedocromil sodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ALOCRIL® ophthalmic solution should be used during pregnancy only if clearly needed.
|
|
NOTE
|
Requires a week or two for effect. Sometimes used to reduce contact lens intolerance.
|
